<DOC>
	<DOCNO>NCT02156336</DOCNO>
	<brief_summary>The purpose trial determine patient suffer diabetic peripheral neuropathic pain treat ranolazine great reduction pain compare placebo . Hypothesis : From prior clinical observation , analgesic efficacy preclinical animal model neuropathic pain , investigator hypothesize subject randomize ranolazine show great reduction diabetic neuropathic pain compare placebo .</brief_summary>
	<brief_title>Ranolazine Diabetic Peripheral Neuropathic Pain ( DPNP )</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>1 . A minimum 18 year age ; 2 . Provided sign Informed Consent Form Health Insurance Portability Accountability Act ( HIPAA ) authorization study approve Institutional Review Board ; 3 . Patients must diabetic peripheral neuropathic pain rat average level six ( 6 ) document daily diary prior baseline visit note Baseline Visit ; 4 . Diabetic stable insulin regimen oral medication regimen determine investigator [ It recommend Hba1c &lt; 9.5 % , make note lab normal value may vary among site . ] ; 5 . Clinical Exam Results : 1 . 5.07 SemmesWeinstein Monofilament Test Subject sense monofilament evoke abnormal response minimum two ( 2 ) five ( 5 ) test location plantar surface foot . 2 . Pin Prick Test Subject experience allodynia , hyperalgesia , sensory loss two ( 2 ) five ( 5 ) test location plantar surface four ( 4 ) dorsum one ( 1 ) foot . 6 . Willing able comply requirement protocol follow direction clinic research staff ; 7 . For female patient : Be postmenopausal ( menses least 2 year ) sterilize , If subject childbearing potential , breastfeeding , negative pregnancy test Baseline ( prerandomization , Day 0 ) , intention become pregnant course study , use one follow contraceptive measure : 1 . Stable regimen hormonal contraception 2 . Intrauterine device 3 . Condoms spermicide 4 . Diaphragm spermicide 1 . History allergy intolerance ranolazine ; 2 . Any condition concomitant medication would preclude safe use ranolazine outline prescribe information sheet ; 3 . In judgment investigator , clinicallysignificant ongoing medical condition might jeopardize patient 's safety interfere absorption , distribution , metabolism excretion study drug ; 4 . In judgment investigator , clinicallysignificant abnormal physical finding screen ( exclude patient 's peripheral neuropathy condition ) ; 5 . Use participation another experimental investigational drug device trial ; 6 . Pregnant breast feeding ; 7 . Cirrhosis liver ; 8 . Psychological addictive disorder ( limited , include example , drug and/or alcohol dependency ) may preclude patient consent compliance , may confound study interpretation ; 9 . Taking moderate strong CYP3A inhibitor ( e.g . diltiazem , verapamil , ketoconazole , itraconazole , clarithromycin , erythromycin , nefazodone , nelfinavir , ritonavir , indinavir , saquinavir ) ; 10 . Taking inducer Cytochrome P450 , family 3 , subfamily A ( CYP3A ) ( e.g . rifampin , rifabutin , rifapentine , phenobarbital , phenytoin , carbamazepine , St. John 's wort ) ; 11 . Renal impairment define calculated serum creatinine clearance &lt; 30ml/min ; 12 . Lower back disorder symptoms present similarly DPNP ; 13 . Family history long QT syndrome ; 14 . Congenital long QT syndrome ; 15 . Subjects take tricyclic antidepressant ; 16 . Subjects take antipsychotic drug ; 17 . Patient take &gt; 850mg metformin BID ; 18 . Any subject currently take pregabalin ; 19 . Any subject currently take gabapentin ; 20 . Any subject currently take MetanxÂ® ; 21 . Any subject currently take continuous longterm narcotic ; 22 . Grapefruit grapefruit containing product ; 23 . Use Pgp inhibitor cyclosporine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetic Peripheral Neuropathic Pain</keyword>
	<keyword>Ranexa</keyword>
	<keyword>Ranolazine</keyword>
	<keyword>Neurology</keyword>
</DOC>